A Randomised, Double-blind, Placebo-controlled Trial With an Open-label Extension to Assess the Pharmacokinetics, Safety, and Efficacy of Empagliflozin Tablets in Paediatric Patients With Chronic Kidney Disease (EMPA-KIDNEY® Kids)
Latest Information Update: 06 Mar 2026
At a glance
- Drugs Empagliflozin (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EMPA-KIDNEY-Kids
- Sponsors Boehringer Ingelheim
Most Recent Events
- 17 Dec 2025 Status changed from not yet recruiting to recruiting.
- 18 Nov 2025 Planned initiation date changed from 7 Nov 2025 to 12 Dec 2025.
- 30 Sep 2025 Planned initiation date changed from 27 Oct 2025 to 7 Nov 2025.